Abseamed

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
21-08-2023
Tabia za bidhaa Tabia za bidhaa (SPC)
21-08-2023

Viambatanisho vya kazi:

epoetin alfa

Inapatikana kutoka:

Medice Arzneimittel Pütter GmbH Co. KG

ATC kanuni:

B03XA01

INN (Jina la Kimataifa):

epoetin alfa

Kundi la matibabu:

Antianemic preparations

Eneo la matibabu:

Anemia; Kidney Failure, Chronic; Cancer

Matibabu dalili:

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy).Abseamed can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (haemoglobin (Hb) 10-13 g/dl [6.2-8.1 mmol/l], no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).Abseamed can be used to reduce exposure to allogeneic blood transfusions in adult non iron deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 10-13 g/dl) who do not have an autologous predonation programme available and with an expected blood loss of 900 to 1800 ml.

Bidhaa muhtasari:

Revision: 22

Idhini hali ya:

Authorised

Idhini ya tarehe:

2007-08-27

Taarifa za kipeperushi

                                75
B. PACKAGE LEAFLET
76
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ABSEAMED 1,000 IU/0.5 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 2,000 IU/1 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
ABSEAMED 3,000 IU/0.3 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 4,000 IU/0.4 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 5,000 IU/0.5 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 6,000 IU/0.6 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 7,000 IU/0.7 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 8,000 IU/0.8 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 9,000 IU/0.9 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 10,000 IU/1 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
ABSEAMED 20,000 IU/0.5 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 30,000 IU/0.75 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 40,000 IU/1 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
Epoetin alfa
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Abseamed is and what it is used for
2.
What you need to know before you use Abseamed
3.
How to use Abseamed
4.
Possible side effects
5.
How to store Abseamed
6.
Contents of the pack and other information
1.
WHAT ABSEAMED IS AND WHAT IT IS USED FOR
Abseamed contains the active substance epoetin alfa, a protein that
stimulates the bone marrow to
produce more red blood cells which carry haemoglobin (a substance that
transports oxygen). Epoe
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe
Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled
syringe
Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled
syringe
Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled
syringe
Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled
syringe
Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled
syringe
Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled
syringe
Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe
Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled
syringe
Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Each mL of solution contains 2,000 IU of epoetin alfa
*
corresponding to 16.8 micrograms per mL
A pre-filled syringe of 0.5 mL contains 1,000 international units (IU)
corresponding to 8.4 micrograms
epoetin alfa. *
Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe
Each mL of solution contains 2,000 IU of epoetin alfa
*
corresponding to 16.8 micrograms per mL
A pre-filled syringe of 1 mL contains 2,000 international units (IU)
corresponding to 16.8 micrograms
epoetin alfa. *
Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled
syringe
Each mL of solution contains 10,000 IU of epoetin alfa
*
corresponding to 84.0 micrograms per mL
A pre-filled syringe of 0.3 mL contains 3,000 international units (IU)
corresponding
to 25.2 micrograms epoetin alfa. *
Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled
syringe
Each mL of solution contains 10,000 IU of epoetin alfa
*

                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kibulgaria 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kihispania 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kicheki 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kidenmaki 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kijerumani 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kiestonia 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kigiriki 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kifaransa 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kiitaliano 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kilatvia 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kilithuania 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kihungari 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kimalta 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kiholanzi 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kipolandi 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kireno 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kiromania 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kislovakia 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kislovenia 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kifinlandi 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kiswidi 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 03-10-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kinorwe 21-08-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 21-08-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 21-08-2023
Tabia za bidhaa Tabia za bidhaa Kroeshia 21-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 03-10-2018

Tafuta arifu zinazohusiana na bidhaa hii

Tazama historia ya hati